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Abstract
We assessed the outcome of patients with drug resistant epilepsy and neuronal antibodies who 
underwent epilepsy surgery. Retrospective study, information collected with a questionnaire sent 
to epilepsy surgery centers. Thirteen patients identified, with antibodies to GAD (8), Ma2 (2), Hu 
(1), LGI1 (1) or CASPR2 (1). Mean age at seizure onset: 23 years. Five patients had an 
encephalitic phase. Three had testicular tumors and five had autoimmune diseases. All had drug 
resistant temporal lobe epilepsy (median: 20 seizures/month). MRI showed unilateral temporal 
lobe abnormalities (mainly hippocampal sclerosis) in 9 patients, bilateral abnormalities in 3, and 
was normal in 1. Surgical procedures included anteromesial temporal lobectomy (10 patients), 
selective amygdalohippocampectomy (1), temporal pole resection (1) and radiofrequency ablation 
of mesial structures (1). Perivascular lymphocytic infiltrates were seen in 7/12 patients. One year 
outcome available in all patients, at 3 years in 9. At last visit 5/13 patients (38.5%) (with Ma2, Hu, 
LGI1, and 2 GAD antibodies) were in Engel`s classes I or II. Epilepsy surgery may be an option 
for patients with drug resistant seizures associated with neuronal antibodies. Outcome seems to be 
worse than that expected in other etiologies, even in the presence of unilateral HS. Intracranial 
EEG may be required in some patients.
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Introduction
Autoimmunity is being increasingly recognized as a cause of drug resistant epilepsy. Some 
patients develop drug resistant seizures after an episode of well-characterized autoimmune 
encephalitis (Pillai et al., 2016). There is also evidence that autoimmune (paraneoplastic or 
non-paraneoplastic) limbic encephalitis may present as temporal lobe epilepsy, sometimes 
associated with hippocampal sclerosis (HS) (Bien et al., 2007;Gaspard, 2016). As neuronal 
antibody determination becomes more widely available, they are increasingly identified in a 
subset of patients with chronic epilepsy during the diagnostic workup.
Patients with autoimmune epilepsy usually have high seizure frequency and often display 
MRI abnormalities, such as HS. In this setting, when antiepileptic and immunosuppressive 
drugs fail, surgical treatment may be a therapeutic option. The HS observed in these patients 
probably represents a “burn out” inflammatory process and it is often considered the 
underlying “structural” cause of the seizures. Less frequently, surgery is performed when the 
autoimmune etiology has not been suspected yet and the mesial temporal swelling is 
mistaken for cortical dysplasia or a low-grade tumor (Almeida et al., 2012). The potential 
role of epilepsy surgery has been only assessed in isolated case reports and small series of 
patients with neuronal antibodies (Almeida et al., 2012;Kerling et al., 2008;Malter et al., 
2015;Muehlebner et al., 2010). The objective of our study was to determine the outcome of a 
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series of patients with epilepsy associated with neuronal antibodies who underwent epilepsy 
surgery.
Methods
This retrospective multicenter study was approved by the Ethics committee of Hospital 
Clínic, University of Barcelona (Barcelona, Spain). Patients were routinely consented for 
their clinical information to be included in clinical studies. A questionnaire was sent to 60 
tertiary epilepsy surgery centers in Europe, USA, Canada, and Japan to find out if they had 
any patients who met the inclusion criteria: resective surgery for drug resistant epilepsy and 
positive neuronal antibodies. We asked about clinical features, acute encephalitic phase if 
present, immunosuppressive treatment, type and titres of autoantibodies if available, results 
of presurgical evaluation, pathological findings, and seizure outcome at 1 and 3 years. 
Surgically treated patients in whom pathological findings were suggestive of chronic 
encephalitis but no specific antibody was found were excluded from the study. Outcome was 
assessed by the Engel classification, a widely used tool to categorize the outcome of 
epilepsy surgery: class I (free of disabling seizures), class II (rare disabling seizures, almost 
seizure free), class III (worthwhile improvement) and class IV (not worthwhile 
improvement). Satisfactory outcome included classes I and II.
Results
Most epilepsy centers could not provide any patients who met the inclusion criteria. Finally, 
a total of 13 patients from 8 centers in Europe and the United States were included in the 
study. Two patients have been previously reported (Almeida et al., 2012;Haberlandt et al., 
2011). Mean age at epilepsy onset was 23 years (range: 2–46 years). The following 
antibodies were detected in serum: GAD (8 patients), Ma2 (2) patients), Hu (1), LGI1 (1), 
and CASPR2 (1). Antibodies were also detected in CSF in 5/11 patients (CSF not analyzed 
in 2). Oligoclonal bands in CSF were found in 3 patients. The antibodies were found after 
surgery in 5 patients (Table 1), most often because of the pathological findings. Eight 
patients had drug resistant epilepsy without a previous episode of encephalitis (6 GAD, 1 
LGI1, 1 CASPR2), whereas the other five patients developed drug resistant epilepsy after a 
typical episode of autoimmune encephalitis. Associated comorbidities included 3 testicular 
tumors (2 anti-Ma2, 1 anti-Hu), and several autoimmune disorders, all in patients with GAD 
antibodies (Table 1). Six patients (five who had encephalitis and one with chronic epilepsy) 
were treated with immunosuppressive drugs (intravenous corticosteroids ± 
immunoglobulins). Three patients were still taking maintenance corticosteroids at 
presurgical evaluation.
Mean time to presurgical evaluation was 9.4 years (range 1–61 years). All patients 
underwent prolonged video-EEG monitoring with surface electrodes, MRI and 
neuropsychological testing. No patients underwent monitoring with invasive electrodes. 
Seizure frequency was daily or monthly (median number: 20 per month, range 2–720). 
Mean number of antiepileptic drugs was 2.1 (range 1–3). All patients had seizures with 
temporal lobe semiology. Ten patients had auras, being abdominal (5 patients), and psychic 
(5) the most common. Four patients displayed multiple types of auras. The most frequently 
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recorded seizures were automotor (with oral or distant hand automatisms and alteration of 
awareness: 11 patients). Two patients had autonomic seizures (objective piloerection). In 
addition, four patients had complex motor seizures with irregular movements involving 
trunk and proximal parts of the limbs and 3 had secondarily generalized tonic-clonic 
seizures. Interictal surface EEG showed unilateral temporal epileptiform discharges in 9/13 
patients, and bilateral temporal discharges in the other 4. Surface ictal EEG showed seizure 
onset zone in one temporal lobe in 9/13 patients and independently in both temporal lobes in 
4/13 patients. Neuropsychological evaluation demonstrated bilateral temporal dysfunction in 
4 patients (one with severe anterograde amnesia), unilateral temporal dysfunction in 7 and 
executive deficits only in 2 patients.
MRI was normal in 1 patient, showed unilateral HS in 6/13 patients, bilateral asymmetric 
HS in 2/13 patients, unilateral increase in size and signal of mesial structures thought to be a 
malformation or a low grade tumor in 3/13 patients and bilateral increase in size and signal 
of mesial temporal structures in 1 patient (Table 1).
Surgical procedures included standard anteromesial temporal resection in 10/13 patients, 
selective amygdalohippocampectomy in 1, resection of the temporal pole sparing the 
hippocampus in 1, and stereotactic radiofrequency ablation of mesial structures in 1. 
Complications after surgery included depression (2 patients), semantic memory deficits (1) 
and quadrantanopsia (1). Neuropathological findings included lymphocytic infiltrates in 7/12 
patients (Figure 1), along with variable amounts of neuronophagic nodules, microglia 
activation, neuronal loss, hippocampal sclerosis, and abnormal cortical lamination (Table 1). 
Seizure outcome was available at 1 year for all patients and at 3 years for 9. At the last 
follow-up, 5/13 patients (38.4%) were in Engel classes I or II; 8 patients were in classes III 
or IV. Two patients became seizure free after surgery. Two patients (CASP2R and GAD) 
who were initially seizure free moved to a class III outcome during follow-up. We did not 
find any correlation between outcome of surgery and antibody type, previous history of 
encephalitis, or presence of uni or bilateral HS in the MRI (only 1 out of 6 patients −16%- 
with HS had a good outcome).
Discussion
This retrospective multicenter study shows that seizure outcome after temporal lobe surgery 
in patients with neuronal antibodies seems to be worse than that in other clinical settings. In 
temporal lobe epilepsy with unilateral HS not associated with neuronal antibodies, up to 
70% of patients become seizure free after surgery (Mathon et al., 2015), whereas only 16% 
of patients with similar MRI findings but with neuronal antibodies became seizure free in 
the current study. We acknowledge that the number of patients is small and this could have 
led to an underestimation of the efficacy of the surgical procedure. However, in view of these 
results it seems reasonable to be cautious when discussing the possibility of seizure freedom 
with patients and their families.
In such a limited sample it is difficult to extract valuable conclusions regarding the influence 
of specific types of neuronal antibodies in surgical outcome. A good clinical outcome 
occurred with different types of onconeural and surface-directed antibodies. Only 2 of 8 
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patients with GAD antibodies became free or almost seizure free in the long-term. This is in 
agreement with previously published series reporting improvement in seizure frequency but 
not seizure freedom in patients with GAD autoimmunity after surgery (Malter et al., 2015).
There are several possible explanations for this type of outcome. First, we have found that 
active signs of inflammation are present not only in patients undergoing surgery during the 
“acute” phase of the disease, but also in some patients with HS, reflecting that residual 
lesions and active inflammation may occur simultaneously in the same patient. Second, the 
ongoing inflammatory process may well extend beyond the surgically resected area (for 
example to the insula) and contribute to seizure generation after surgery. The occurrence of 
prominent autonomic symptoms in some patients suggests involvement of the insular cortex 
in seizure generation or epileptic network. Consequently, failure to identify a “temporal 
plus” epilepsy could explain failure of surgery in some cases (Barba et al., 2016). Third, the 
setting of neuronal antibodies it is not uncommon to observe bilateral involvement of the 
temporal lobes, both structurally (MRI) and functionally (e.g. memory deficits, bilateral 
interictal epileptiform discharges, bilateral seizure onset in the ictal EEG). Therefore, the 
non-resected temporal lobe may become epileptogenic, particularly if there is an ongoing 
inflammatory process in the brain. (Kerling et al., 2008). Intracranial EEG should be 
considered in patients with a possible temporal plus or bitemporal epilepsy to delineate 
better the seizure onset zone and increase the likelihood of successful epilepsy surgery.
Our study has several limitations. The main one is the small number of patients. However 
these patients are extremely difficult to find. We managed to include 13 after contacting with 
60 of the most active epilepsy surgery centers in the world. The reason is that they are very 
rarely considered for surgery, even after antiepileptic and immunosuppressive drugs have 
failed. In fact, in 4 patients the resection was performed before the antibodies were 
discovered, when a possible autoimmune etiology had not been suspected yet. It is possible 
that epileptologists consider autoimmune epilepsy as an entity less likely to result in seizure 
freedom after surgery, due to its widespread epileptogenic effects. Our series seems to 
confirm this belief.
Due to its retrospective design, the study has the inherent bias that only patients with 
selected “favorable” clinical and MRI features underwent presurgical evaluation 
(presumably those deemed to have some benefit from surgery). In addition, the titers of 
GAD antibodies were not available for many patients. However, we believe our findings add 
valuable information to the decision algorithm in patients with drug resistant seizures and 
neuronal antibodies that we encounter with increasing frequency in our practice. Taking into 
account the high seizure frequency and the low rate of surgery complications, the possible 
benefit of a palliative resection may be considered. Presurgical evaluation may require 
invasive EEG studies in some patients.
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• Surgery is sometimes performed for temporal lobe epilepsy with neuronal 
antibodies
• Surgery outcome is poorer than in patients without neuronal antibodies
• No clear relationship between outcome and antibody type or MRI lesion was 
found
• Presence of unilateral HS does not necessarily associate to good outcome
• Invasive studies may help in some patients to define better the seizure onset 
zone
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A, B: Coronal FLAIR MRI images showing increased signal and volumen of right amígdala 
and hippocampus, suggestive of limbic encephalitis, in a patient with acute onset of seizures. 
The patient had anti Ma2 antibodies and a past history of seminoma (patient 1, see table).
C, D: Coronal FLAIR images one year later, showing atrophy of right mesial temporal 
structures with persistence of the increased signal (right MTS) (patient 1)
E: SISCOM showing increased ictal perfusion over the right hippocampus and 
parahippocampal gyrus during a right temporal lobe seizure with epigastric aura, 
piloerection and loss of awareness (patient 1).
F: Coronal FLAIR image showing resection of the temporal pole and the right mesial 
temporal structures. The patient continued to have seizures after surgery although with some 
seizure reduction (Engel´s class III) (patient 1)
G: Inflammatory infiltrate in the surgical specimen. The tissue section was immunostained 
with TIA-1 antibody, a marker of cytotoxic T cells. There are positive cells clearly showing 
the characteristic TIA-1 granular pattern in the inflammatory infiltrate. Some TIA-1 positive 
cells are in close apposition with neurons (H). (patient 1)
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